Eisai Inc.’s new U.S. headquarters in Nutley supports what the pharmaceutical company described as a hybrid, technologically advanced work setting and its pursuit of treatments for cancer, Alzheimer’s disease and other neurodegenerative diseases. — Photos courtesy: Eisai
By Joshua Burd
A pharmaceutical company has opened its new U.S. headquarters in Nutley, where it occupies some 300,000 square feet as part of Prism Capital Partners’ acclaimed ON3 campus.
Eisai Inc., the U.S. subsidiary of Tokyo-based Eisai Co. Ltd., moved to the space at 200 Metro Blvd. from a previous location in Woodcliff Lake. The modern office supports what the company described as a new hybrid, technologically advanced work setting and its pursuit of treatments for cancer, Alzheimer’s disease and other neurodegenerative diseases.
It’s also the site of the largest office lease to date at ON3, Prism’s adaptive reuse of the 116-acre former Hoffmann-LaRoche campus in Nutley and Clifton. Eisai signed the lease in 2020, around six months into the COVID-19 crisis in New Jersey, and now occupies the landmark glass and marble 15-story office tower long visible to area residents and motorists.
“Eisai’s decision to relocate to the ON3 campus is a demonstration of our ongoing commitment to New Jersey and to be part of this diverse life sciences hub,” said Tatsuyuki Yasuno, president of Eisai Inc. and the company’s Americas region. “With a 400-seat auditorium and an Innovation Center at our new U.S. headquarters, we are establishing dedicated space and resources to educate and motivate our employees, as well as a forum to hear from patients, advocacy partners and the community. Through this collaboration, we can make a positive impact on people and society and fulfill our human health care mission.”
Cushman & Wakefield’s Robert Rudin, Bill Brown and Josh Cohen represented Prism in the deal, which recently won NAIOP New Jersey’s Office Deal of the Year Award. Savills’ Gregg Najarian, Daniel Foley, Chip Conklin and Nathan Brzozowski represented the tenant, while SJP Project Solutions managed the build-out of the space.
The space initially will house around 800 employees and some 1,300 at full capacity, Eisai said, with a design that allows for collaboration and interaction among colleagues while encouraging them to embrace hybrid work in a post-COVID environment. The company’s U.S. presence also includes three early-stage discovery research centers, as well as commercial, clinical development and global demand organizations.
“Eisai is a global pharmaceutical company, committed to human health care, who values the communities where they work,” Nutley Mayor Mauro G. Tucci said. “We welcome Eisai to Nutley and look forward to working with them to enhance our township. We thank them for their investment in our community and the surrounding area.”
Prism acquired the Route 3 campus in late 2016, some four years after Roche said it would vacate its North Jersey home of more than 80 years, and has spent the past five years luring major users as it pursues a sweeping long-term plan for the property. New users at the site include the Hackensack-Meridian School of Medicine at Seton Hall University and Seton Hall’s Graduate College of Nursing and School of Health and Medical Sciences, along with Modern Meadow, Ralph Lauren Corp. and Quest Diagnostics.
The developer ultimately aims to build a walkable, downtown-style environment and has previously proposed adding retail, multifamily and hospitality components, along with additional office and health care users.
“New Jersey has established itself as the global epicenter of the biopharmaceutical industry, and we are proud to see an innovative company like Eisai call Clifton home,” Clifton Mayor James Anzaldi said. “Given the urgency for new treatments for cancer and neurologic conditions, we look forward to seeing the important work Eisai is doing make a positive societal impact and improve the lives of our residents and people around the world.”